+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are evaluating the efficacy and safety of eloralintide in adults with moderate-to-severe obstructive sleep apnea OSA who are also obese or overweight. The study uses a master protocol called YDAO that includes two separate studies YSA1 for participants who cannot or do not want to use Positive Airway Pressure PAP therapy, and YSA2 for those who have been on PAP therapy for at least three months and plan to continue it during the study. The goal is to understand how eloralintide affects body weight and sleep apnea severity. Participants will be randomly assigned to receive either eloralintide or a placebo, both given as weekly subcutaneous injections. The study lasts about 76 weeks and includes two groups based on PAP therapy use. During the study, participants will continue their current PAP therapy status according to their assigned group. The study is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the study, participants will undergo assessments at baseline and Week 64, including measuring changes in body weight, apnea-hypopnea index AHI, blood pressure, triglycerides, sleep-related impairment, and other health markers. Researchers will also monitor safety, medication use, and pharmacokinetics. Participants can expect regular visits for evaluations and monitoring over the study period to understand the effects of eloralintide on OSA and obesity-related health factors.

Age: 18Years +All GendersPhase 3
115 locations
O

Actively Recruiting

Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.

Age: 18Years +All Genders
92 locations
E

Actively Recruiting

Researchers are investigating how access to peri-implant probing relates to bone loss around dental implants, a condition called peri-implantitis. This study is observational and cross-sectional, enrolling patients who have had dental implants in place for at least three years. The goal is to understand whether limited access to probing, due to prosthetic design, affects the diagnosis and progression of bone loss. Participants will undergo standard clinical exams including probing depth measurements at six sites per implant using manual or flexible probes when access is limited. Clinical signs such as plaque, bleeding, and suppuration will be recorded. Radiographic images will be taken to assess bone levels. No treatments or changes to prosthetic designs or care protocols will be made during this study. During the single study visit, clinical, radiographic, and prosthetic data will be collected to evaluate probing accessibility and its association with bone loss. Researchers will analyze the relationship between probing access and peri-implant bone loss at both the patient and implant levels. The study involves no interventions, and participation includes one baseline assessment with no ongoing treatment or follow-up required.

All AgesAll Genders
9 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of the drug NNC0487-0111 in adults with excess body weight and moderate-to-severe obstructive sleep apnoea OSA who are not treated with positive airway pressure. This Phase 3 study randomizes participants to receive either NNC0487-0111 or a placebo to assess their ability to lose weight and improve sleep apnoea symptoms. Participants will receive weekly injections under the skin using pre-filled pen-injectors of either NNC0487-0111 or placebo. Both groups will follow a reduced-calorie diet and increase physical activity. The treatment period lasts 80 weeks, during which the effects on body weight and sleep apnoea will be monitored. During the study, participants will have regular assessments including measurements of body weight, apnoea-hypopnoea index AHI, sleepiness scales, blood pressure, cholesterol levels, blood sugar, and other health indicators. Safety will be monitored through tracking adverse events up to 84 weeks. The study aims to measure changes from baseline to week 80 to evaluate treatment impact.

Age: 18Years +All GendersPhase 3
80 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of a medicine called NNC0487-0111 in adults with overweight or obesity who also have moderate-to-severe obstructive sleep apnoea OSA treated with positive airway pressure. This Phase 3 study compares NNC0487-0111 to a placebo to see how well it helps reduce body weight and improve sleep apnoea symptoms over time. Participants will be randomly assigned to receive one of these treatments, which are injected under the skin weekly. Participants will receive either one of two dose levels of NNC0487-0111 or a matching placebo injection once a week. Both groups will also follow a reduced-calorie diet and increase physical activity as part of the study. The injections are given using pre-filled pen-injectors at areas such as the thigh, abdomen, or upper arm. The treatment period lasts up to 80 weeks, during which body weight and sleep apnoea severity are closely monitored. Throughout the study, participants will have regular assessments to measure changes in body weight, apnoea-hypopnoea index AHI, sleep quality, blood pressure, blood sugar, cholesterol, and other health markers. Safety is monitored by tracking adverse events until week 84. The study also evaluates improvements in sleep-related symptoms and the potential to reduce or stop positive airway pressure therapy. Total participation may last up to 84 weeks, including follow-up for safety and health outcomes.

Age: 18Years +All GendersPhase 3
92 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
S

Actively Recruiting

This observational clinical follow-up study is designed to evaluate the safety of immunotherapy for treating hymenoptera venom allergy in real-life conditions. It focuses on patients allergic to venom from Apis mellifera bee or Vespula spp. wasp and includes the assessment of both controlled and spontaneous stings. The study is multicentric and will be conducted in Spain with prospective data collection. Participants will receive VENOX immunotherapy, an allergy vaccine targeting venom from wasps or bees, as per clinical recommendations. The study will follow patients for 12 months to monitor safety and tolerability, particularly the incidence of treatment-emergent adverse reactions. It also evaluates treatment effectiveness after reaching a maintenance dose and assesses immunological parameters and quality of life using the SEAIC questionnaire. During the study, participants will be observed over one year with regular follow-ups to collect data on adverse reactions and treatment impact. Researchers will monitor spontaneous natural stings and measure immunological changes. Quality of life related to venom allergy will also be assessed. The total number of participants is expected to be 80, all aged 14 years or older, and of any gender.

Age: 14Years +All Genders
3 locations
L

Actively Recruiting

Researchers are conducting a multicenter observational study to gather long-term information from patients diagnosed with early-stage invasive breast cancer. These patients have previously participated in neoadjuvant or adjuvant clinical trials conducted by the GEICAM group. The study aims to provide data on the long-term outcomes and sequelae related to breast cancer treatments beyond the original trial follow-up periods. Participants are included after completing follow-up in their original GEICAM clinical trials and will be observed for approximately 30 years. This extended observation allows for evaluation of event-free survival and disease-free survival over a long duration. The study collects ongoing data without providing additional interventions. During the study, participants will be monitored through data collection related to survival outcomes, including overall survival, event-free survival, and disease-free survival. This long-term follow-up provides valuable information for healthcare professionals, patients, and society regarding the evolution and management of early-stage invasive breast cancer. Participation involves no new treatment, only data collection over many years.

Age: 18Years +FEMALE
73 locations
C

Actively Recruiting

The trial investigates treatment options for adults with newly diagnosed multiple myeloma who are eligible for stem cell transplantation. It is a Phase III, open-label, randomized study comparing three treatment approaches to evaluate their effectiveness in achieving minimal residual disease negativity using next-generation flow cytometry. The study aims to compare an extended VRD regimen plus early rescue intervention with two Isatuximab-containing regimens. Participants are assigned to one of three groups Arm A receives Isatuximab combined with VRD followed by autologous stem cell transplant ASCT, then consolidation and continuous treatment with Lenalidomide and monthly Isatuximab Arm B receives an extended VRD regimen with ASCT plus early rescue intervention involving Isatuximab-Iberdomide-Dexamethasone, followed by consolidation and continuous treatment with adjusted VRD cycles Arm C is treated with Isatuximab, Iberdomide, VRD, and ASCT, followed by consolidation and continuous treatment with Iberdomide and monthly Isatuximab. Each treatment phase includes induction, ASCT, consolidation, and continuous therapy lasting approximately 24 months or longer. Throughout the study, participants undergo multiple cycles of treatment with frequent dosing schedules, including intravenous infusions and oral medications. Researchers assess the primary outcome by measuring the proportion of participants who are MRD-negative after 18 cycles plus ASCT, approximately 24 months. Safety and progression-free survival are monitored over about 78 months. The study also involves bone marrow analyses, adherence tracking, and reviews of therapeutic programs up to 36 months. Participants are followed closely for treatment response and adverse events during and after therapy.

Age: 18Years - 65YearsAll GendersPhase 3
68 locations

1-10 of 16

1